 | | Vol. 12.08 – 5 March, 2021 |
| |
|
|
| Researchers used single-cell transcriptomics and validation in external cohorts to characterize metastatic castration-resistant prostate cancer expression programs in the context of therapy.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Puberty induced the formation of further side and terminal branches by local stem cells disseminated throughout the rudimentary ducts during development. During adult tissue maintenance, clonal expansions have limited geographic scope and minimal migration.
[Cell Stem Cell] |
|
|
|
| By assessing multiple discrete areas across multiple metastases, the authors found a high level of intra-patient homogeneity with respect to tumor phenotype.
[Nature Communications] |
|
|
|
| Scientists identified prostate cancer susceptibility single nucleotide polymorphisms at an intronic enhancer of the NEDD9 gene, which is strongly associated with increased risk of patients with African ancestry.
[Cancer Research] |
|
|
|
| A functional effect of Peroxisome Proliferator-Activated Receptor (PPAR)-Gamma on AKT serine/threonine kinase 3 (AKT3), which ultimately resulted in a more aggressive disease phenotype was identified.
[Oncogene] |
|
|
|
| Innovated AR-independent therapy might alleviate enzalutamide resistance and prevent the production of adverse side effects. Researchers identified that yes-associated protein 1 (YAP1) was overexpressed in enzalutamide-resistant cells.
[Oncogene] |
|
|
|
| Whereas both JUN and FOS have been implicated in prostate cancer, the authors provided evidence that FOS acts as a tumor suppressor during prostate cancer progression and invasion.
[Oncogene] |
|
|
|
| Investigators showed that specific small RNAs downregulate the expression of multiple essential and androgen receptor-coregulatory genes, leading to potent androgen signaling inhibition and prostate cancer cell death.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| The molecule potently inhibited cell growth, colony formation, and mRNA expression of AR-regulated genes in prostate cancer cell lines.
[Acta Pharmacologica Sinica] |
|
|
|
|
| Scientists describe the landscape of prostate-specific membrane antigen (PMSA)-based therapies beyond 177Lu-PSMA-617.
[European Urology Focus] |
|
|
|
|
| Quibim announced the launch of qp-Prostate, its latest and most advanced prostate AI-based Magnetic Resonance (MR) solution, after receiving 510(k) clearance by the FDA.
[Quibim (PR Newswire, LLC)] |
|
|
|
|
| June 14 – 18, 2021
Virtual |
|
|
|
|
|
| | Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| | H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| | Weill Cornell Medicine – New York, New York, United States |
|
|
|
| | CyberCoders – San Diego, California, United States |
|
|
|
| | University of Notre Dame – Notre Dame, Indiana, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
